EUCTR2014-002264-33-DK进行中（未招募）1 期
Rifaximin in alcoholic hepatitis: effects on inflammatory and metabolic markers.
Ole Hamberg0 个研究点目标入组 30 人开始时间: 2014年7月3日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Alcohol intake > 30 g daily for more than 3 months or > 100 g daily for more than 4 weeks.
- •Increased plasma-bilirubin level (>80 mikromol/l)
- •No mechanical bile duct obstruction.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 28
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •Age < 18 years
- •Treatment with rifaximin within the last 4 weeks
- •Allergi towards rifaximin
- •Bowel obstruction
研究者
相似试验
Unknown
2 期
Effects of Rifaximin in Patients With Acute Alcoholic HepatitisAlcoholic HepatitisNCT02116556Hospital Universitari Vall d'Hebron Research Institute29
Unknown
3 期
Rifaximin Use in Severe Alcoholic HepatitisSevere Alcoholic HepatitisNCT02485106Saint Vincent's Hospital, Korea170
已完成
不适用
The effect of rifaximin on liver cirrhosis patients with hepatic encephalopathyJPRN-UMIN000032548ara Medical University50
已完成
不适用
Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis PatientsSteatohepatitisFatty LiverNCT02009592Bezmialem Vakif University42
招募中
不适用
Efficacy of rifaximin for the treatment of hepatic encephalopathy through the intestinal permeability: an open-label, single-arm, singlecenter, pilot studyhepatic encephalopathyJPRN-UMIN000032308Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan30